Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
- PMID: 29571804
- DOI: 10.1016/j.ejrad.2018.01.025
Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
Erratum in
-
Corrigendum to "Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines" [Eur. J. Radiol. 101 (2018) 72-81].Eur J Radiol. 2019 Mar;112:229. doi: 10.1016/j.ejrad.2019.01.018. Epub 2019 Jan 30. Eur J Radiol. 2019. PMID: 30709654 No abstract available.
Abstract
One of the key strategies to improve the prognosis of HCC, beside prevention, is to diagnose the tumor in early stages, when the patient is asymptomatic and the liver function is preserved, because in this clinical situation effective therapies with survival benefit can be applied. Imaging techniques are a key tool in the surveillance and diagnosis of HCC. Screening should be based in US every 6 months and non-invasive diagnostic criteria of HCC based on imaging findings on dynamic-MR and/or dynamic-CT have been validated and thus, accepted in clinical guidelines. The typical vascular pattern depicted by HCC on CT and or MRI consists on arterial enhancement, stronger than the surrounding liver (wash-in), and hypodensity or hyposignal intensity compared to the surrounding liver (wash-out) in the venous phase. This has a sensitivity of around 60% with a 96-100% specificity. Major improvements on liver imaging have been introduced in the latest years, adding functional information that can be quantified: the use of hepatobiliary contrast media for liver MRI, the inclusion of diffusion-weighted sequences in the standard protocols for liver MRI studies and new radiotracers for positron-emission tomography (PET). However, all them are still a matter of research prior to be incorporated in evidence based clinical decision making. This review summarizes the current knowledge about imaging techniques for the early diagnosis and staging of HCC, and it discusses the most relevant open questions.
Keywords: Cirrhosis; Contrast-enhanced ultrasonography; Diagnosis; Dynamic imaging techniques; Hepatocellular carcinoma.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis.World J Gastroenterol. 2018 Jun 14;24(22):2348-2362. doi: 10.3748/wjg.v24.i22.2348. World J Gastroenterol. 2018. PMID: 29904242 Free PMC article. Review.
-
Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis.PLoS One. 2016 Nov 9;11(11):e0166157. doi: 10.1371/journal.pone.0166157. eCollection 2016. PLoS One. 2016. PMID: 27829060 Free PMC article.
-
Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.BMC Cancer. 2017 Dec 21;17(1):877. doi: 10.1186/s12885-017-3819-y. BMC Cancer. 2017. PMID: 29268722 Free PMC article.
-
Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines.Korean J Radiol. 2019 Jun;20(6):863-879. doi: 10.3348/kjr.2018.0450. Korean J Radiol. 2019. PMID: 31132813 Free PMC article. Review.
-
Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.Radiology. 2015 Jan;274(1):149-60. doi: 10.1148/radiol.14140141. Epub 2014 Sep 5. Radiology. 2015. PMID: 25203131
Cited by
-
Automatic volumetric diagnosis of hepatocellular carcinoma based on four-phase CT scans with minimum extra information.Front Oncol. 2022 Oct 13;12:960178. doi: 10.3389/fonc.2022.960178. eCollection 2022. Front Oncol. 2022. PMID: 36313647 Free PMC article.
-
MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma.Oncol Lett. 2021 Jul;22(1):549. doi: 10.3892/ol.2021.12810. Epub 2021 May 24. Oncol Lett. 2021. PMID: 34093770 Free PMC article.
-
Misdiagnosis Based on Neoplastic Markers-Extremely High Alpha-Fetoprotein in Patients with Intrahepatic Cholangiocarcinoma with Literature Review of the Published Cases.Medicina (Kaunas). 2024 Jul 9;60(7):1109. doi: 10.3390/medicina60071109. Medicina (Kaunas). 2024. PMID: 39064538 Free PMC article. Review.
-
Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma.Metabolites. 2024 Sep 23;14(9):513. doi: 10.3390/metabo14090513. Metabolites. 2024. PMID: 39330520 Free PMC article.
-
Biomarkers for hepatocellular carcinoma: What's new on the horizon?World J Gastroenterol. 2018 Sep 21;24(35):3974-3979. doi: 10.3748/wjg.v24.i35.3974. World J Gastroenterol. 2018. PMID: 30254402 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical